# US 2023/0068944 A1 · Liquid nimodipine compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068944 A1
- Document ID: US20230068944A1
- Status: Published application
- Kind: A1
- Application number: 17/974,027
- Filed: 2022-10-26
- Published: 2023-03-02
- Earliest claimed: 2018-01-25
- Assignees: Azuirty Pharmaceuticals, LLC
- Applicants: Azuirty Pharmaceuticals, LLC
- Inventors: Hugh Greg Thomas
- Web page: https://patentgrep.com/patent/US20230068944A1

## CPC

- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

A method of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms comprising enterally administering to a patient in need thereof an effective amount of a liquid composition comprising nimodipine and a solvent system from about 50% to about 97% (w/v) PEG, about 1 to about 10% (w/v) water, from about 0.4% to about 1% (w/v) ethanol, and from about 1% to about 50% (w/v) glycerin, wherein the concentration of nimodipine is about 6 mg/mL or greater or about 12 mg/ml.

### Claim 16 (depends on 15)

The method of claim 15, wherein the solvent system consists of PEG, water, ethanol, and glycerin.

### Claim 17 (depends on 15)

The method of claim 15, wherein the solvent system comprises from about 0.5% to about 1% (w/v) ethanol.

### Claim 18 (depends on 15)

The method of claim 15, wherein nimodipine is present in an amount of about 60 mg per dosage unit.

### Claim 19 (depends on 15)

The method of claim 15, wherein about 5% or less nimodipine degradation is observed over a period of at least six months when exposed to 40° C. and 75% relative humidity.

### Claim 20 (depends on 15)

The method of claim 15, wherein the composition is administered orally, via nasogastric tube or via gastric tube.

### Claim 21 (depends on 15)

The method of claim 15, wherein a first unit dose of the composition is administered to the patient within about 100 hours of the subarachnoid hemorrhage.

### Claim 22 (depends on 15)

The method of claim 15, wherein the composition is administered multiple times per day.

### Claim 23 (depends on 15)

The method of claim 15, wherein the duration of treatment is continued for at least 7 days.

### Claim 24 (depends on 15)

The method of claim 15, wherein the duration of treatment is continued for at least 14 days.

### Claim 25 (depends on 15)

The method of claim 15, wherein the duration of treatment is continued for at least 21 days.

### Claim 26 (depends on 15)

The method of claim 15, wherein the composition is administered about every four hours.

### Claim 27 (depends on 18)

The method of claim 18, wherein a dosage unit of the liquid composition is administered every four hours for 21 days.

### Claim 28 (depends on 15)

The method of claim 15, wherein the method provides at least 10% decrease in instances of diarrhea compared to NYMALIZE® in instances measured over the period of a week.
